Vaccine, MMR information from DrugsUpdate
L - Caution when used during lactation
The MMR vaccine is a mixture of three live attenuated viruses, administered via injection for immunization against measles, mumps and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5). The second dose is not a booster; it is a dose to produce immunity in the small number of persons (2–5%) who fail to develop measles immunity after the first dose.
It is widely used around the world; since introduction of its earliest versions in the 1970s, over 500 million doses have been used in over 60 countries. As with all vaccinations, long-term effects and efficacy are subject to continuing study. The vaccine is sold by Merck as M-M-R II, GlaxoSmithKline Biologicals as Priorix, Serum Institute of India as Tresivac, and sanofi pasteur as Trimovax.
It is usually considered a childhood vaccination. However, it is also recommended for use in some cases of adults with HIV.
Vaccine, MMR contains live attenuated measles, mumps and rubella viruses. It is used in the active immunisation against these diseases.
Injection-site reactions such as pain and induration. Fever, rash, measles-like rash.
Patients with history of cerebral injury or seizures. Patients with thrombocytopenia and those who develop thrombocytopenia after 1st dose. For patients with active tuberculosis, tuberculosis treatment should be started before using the vaccine. Vaccination may be deferred in patients with moderate or severe acute illness. Pregnancy should be avoided for 28 days after vaccination. Lactation.
Immune globulins may reduce the efficacy of vaccines. May reduce the diagnostic effect of tuberculin tests.
Potentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of vaccines; may also reduce the efficacy of vaccines.
Active immunisation against measles, mumps and rubella
Adult: Given by IM or SC (if there is bleeding disorder). A complete course consists of 2 doses of 0.5 ml; ensure an interval of 3 months between the 2 doses. If protection against measles is needed urgently, the 2nd dose may be given 1 month after the 1st dose. For protection against measles after exposure, doses should be given within 72 hours of contact.
Child: Given by IM or SC (if there is bleeding disorder). ≥12 months: A complete course consists of 2 doses of 0.5 ml; 1st dose to be given ahortly after 1 year old and the 2nd dose to be given before school entry. Doses may be given at any age, allowing an interval of 3 months between the 2 doses. If the vaccine is administered before the child is 1 year old, re-immunisation with the standard 2 doses is necessary when the child is ≥12 months old. If protection against measles is needed urgently, the 2nd dose may be given 1 month after the 1st dose; if the 2nd dose is given before the child is 18 months old, the child should receive the routine dose before starting school at 3-5 years old. For protection against measles after exposure: MMR vaccine may be used in susceptible children >6 months old and doses should be given within 72 hours of contact; these children should still receive the routine MMR vaccine at the recommended ages.
Reconstitute vaccine with the provided diluent. Mix thoroughly. Discard if powder does not dissolve. Use immediately after reconstitution.
List of Contraindications
Contraindicated in pregnancy
Caution when used during lactation
Current febrile respiratory illness or other febrile infection. Patients receiving immunosuppressive therapy; primary and acquired immunodeficiency states. Blood dyscrasias, cancers affecting the bone marrow or lymphatic systems. Pregnancy. Active untreated tuberculosis.
Powder: Store at 2-8°C. Freezing does not affect potency. Diluent: May store in refrigerator or at room temperature; do not freeze. Reconstituted solution: Store at 2-8°C; protect from light; discard if not used within 8 hours.